Post-Marketing Safety of Tazemetostat in Antitumor Therapy: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System
Clinicians need to monitor safety for tazemetostat during the first 30 days and pay more attention to new AE signals.
Authors
- Chunyong Xia
- Lingyun Hu (ORCID: https://orcid.org/0000-0002-1337-9123)
- Lei Zhang (ORCID: https://orcid.org/0000-0002-9702-6738)
- Jun Chen (ORCID: https://orcid.org/0000-0001-7397-2714)
- Jie Liu (ORCID: https://orcid.org/0000-0002-4530-1443)
Institutions
- Chongqing Maternal and Child Health Hospital (CN)
- Jiangjin Central Hospital (CN)
- Children's Hospital of Chongqing Medical University (CN)
- Chongqing Medical University (CN)
Publication Details
- Journal
- Cancer Investigation
- Published
- 2025-12-19
- DOI
- https://doi.org/10.1080/07357907.2025.2598038
- Primary Topic
- Pharmacovigilance and Adverse Drug Reactions
- Type
- article
- Field-Weighted Citation Impact
- 0.00